PolyNovo CFO Jan Gielen to Depart by January 2027
Long-serving chief financial officer Jan Gielen will leave PolyNovo to join Vitrafy Life Sciences.
Updated on Oct. 19, 2026 in Corporate Finance
PolyNovo has announced that Chief Financial Officer Jan Gielen is set to step down from his role on 15 January 2027. Gielen will depart the company to join Vitrafy Life Sciences after eight years of service.
Why it matters
The leadership change marks a significant transition for PolyNovo, which has seen substantial financial growth during Gielen's tenure. The firm is currently working with an external search agency to secure an interim replacement before his departure.
PolyNovo reported annual revenue of $150 million for fiscal year 2026, compared to $13.7 million in fiscal year 2019. The company is currently engaged in a search for an interim chief financial officer.
The players
Jan Gielen
He is the outgoing chief financial officer of PolyNovo who is moving to Vitrafy Life Sciences after an eight-year tenure.
PolyNovo
This Australian-based medical device company specialises in developing and manufacturing innovative dermal scaffolds.
Vitrafy Life Sciences
This life sciences organisation is the firm Jan Gielen will be joining following his departure from PolyNovo.
The details
Jan Gielen, who has been with the organisation for eight years, will transition to his new position at Vitrafy Life Sciences following his departure from PolyNovo. An external executive search firm has been commissioned to manage the search for an interim successor to maintain financial operations during the transition.
Timeline
PolyNovo annual revenue reached $13.7 million in FY19.
PolyNovo annual revenue reached $150 million in FY26.
Jan Gielen will step down from his role on 15 January 2027.
Market Dynamics
The leadership change at PolyNovo follows broader Australian corporate trends for executive transitions as identified by the Australian Institute of Company Directors' executive turnover benchmarks. This shift highlights a competitive environment for financial leadership talent across the Australian biotech sector.
Shareholders and market observers should monitor for further updates regarding the appointment of an interim chief financial officer to ensure stability in financial reporting. The transition signals a significant shift in corporate leadership at a time of record revenue growth for the firm.
The takeaway
Investors should watch for the announcement of an interim successor to ensure continuity in the company's financial governance. The transition underscores the importance of planned executive succession as PolyNovo continues to scale its operations.
Further reading
For more context on executive movements, visit the Australia Corporate Finance section.
